Third, as an exploratory model, it requires more comprehensive validation, including the characterization of intestinal urate transporters and gut microbiota dynamics, systematic evaluation of MSU deposition patterns across multiple organs, and investigation of pathological targets, mechanisms, and genetic signatures associated with progressive hyperuricemia in this model. This evidence concerns the gene SLC2A9 and hyperuricemia.